β2 Adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury

Surgery

Volumn 145, Issue 2, 2009, Pages 235-242

  Rough, James ^a   Engdahl, Ryan ^a   Opperman, Kay ^a   Yerrum, Smitha ^a   Monroy, M Alexandra ^a   Daly, John M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; YOHIMBINE; LIPOPOLYSACCHARIDE; LY96 PROTEIN, MOUSE; PROPANOLAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURGICAL INJURY; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BLEEDING; DRUG ANTAGONISM; IMMUNOLOGY; MACROPHAGE; METABOLISM; MULTIPLE TRAUMA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPINEPHRINE; FEMALE; HEMORRHAGE; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MACROPHAGES; MICE; MICE, INBRED BALB C; MULTIPLE TRAUMA; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 58349114669     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.09.013     Document Type: Article

References (31)

1. Moore F.A., and Moore E.E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 75 (1995) 257-277
2. Woolf P.D., McDonald J.V., Feliciano D.V., Kelly M.M., Nichols D., and Cox C. The catecholamine response to multisystem trauma. Arch Surg 127 (1992) 899-903
3. Mangano D.T., Layug E.L., Wallace A., and Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335 (1996) 1713-1720
4. Pasternack P.F., Grossi E.A., Baumann F.G., Riles T.S., Lamparello P.J., Giangola G., et al. Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am J Surg 158 (1989) 113-116
5. Auerbach A.D., and Goldman L. Beta blockers and reduction of cardiac events in noncardiac surgery. JAMA 287 (2002) 1435-1444
6. Lidenauer P.K., Pekow P., Kaijun W., Mamidi D.K., Guiterrez B., and Benjamin E.M. Perioperative beta blocker therapy and mortality after major noncardiac surgery. N Eng J Med 353 (2005) 349-361
7. Suzuki M., Morisaki H., Serita R., Yamamoto M., Kotake Y., Ishizaka A., et al. Infusion of the beta adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 33 (2005) 2294-2301
8. Cammarat G., Weil M.H., Sun S., Tang W., and Wang J. Beta1 adrenergic blockade during cardiopulmonary resuscitation improves survival. Crit Care Med 32 9 Suppl (2004) S440-S443
9. Schledowski M., Hosch W., Oberbeck R., Benschop R.J., Jacobs R., Raab H.R., et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta-2 adrenergic mechanisms. J Immunol 156 (1996) 93-99
10. Benschop R.J., Jacobs R., Sommer B., Schurmeyer T.H., Raab J.R., Schmidt R.E., et al. Modulation of the immunologic response to acute stress in human by beta-blockade or benzodiazepines. FASEB J 10 (1996) 517-524
11. Strong V.E., Mackrell P.J., Concannon E.M., Naama H.A., Schaefer P.A., Shaftan G.W., et al. Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock 14 (2000) 374-379
12. Maddali S., Stapleton P.P., Freeman T.A., Smyth G.P., Duff M., Yan Z., et al. Neuroendocrine responses mediate macrophage function after trauma. Surgery 136 (2004) 1038-1046
13. Mackrell P.J., Daly J.M., Mestre J.R., Stapleton P.P., Howe L.R., Subbaramaiah K., et al. Elevated expression of cyclooxygenase-2 contributes to immune dysfunction in a murine model of trauma. Surgery 130 (2001) 826-833
14. Mack Strong V.E., Mackrell P.J., Concannon E.M., Mestre J.R., Smyth G.P., Schaefer P.A., et al. NS-398 treatment after trauma modifies NF-kappaB activation and improves survival. J Surg Res 98 (2001) 40-46
15. Stapleton P.P., Strong V.E., Freeman T.A., Winter J., Yan Z., and Daly J.M. Gender affects macrophage cytokine and prostaglandin E2 production and PGE2 receptor expression after trauma. J Surg Res 122 (2004) 1-7
16. Takahashi H.K., Iwagaki H., Mori S., Yoshino T., Tanaka N., and Nishibori M. Beta 2-adrenergic receptor agonist induces IL-18 production without IL-12 production. J Neuroimmunol 151 (2004) 137-147
17. Tan K.S., Nackley A.G., Satterfield K., Maixner W., Diatchenko L., and Flood P.M. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 19 (2007) 251-260
18. Severn A., Rapson N.T., Hunter C.A., and Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 148 (1992) 3441-3445
19. Miksa M., Wu R., Zhou M., and Wang P. Sympathetic excitotoxicity in sepsis: pro-inflammatory priming of macrophages by norepinephrine. Front Biosci 10 (2005) 2217-2229
20. Arbabi S., Campion E.M., Hemmila M.R., Barker M., Dimo M., Ahrns K.S., et al. Beta-blocker use is associated with improved outcomes in adult trauma patients. J Trauma 62 (2007) 56-61
21. Arbabi S., Ahrns K.S., Wahl W.L., Hemmila M.R., Wang S.C., Brandt M.M., et al. Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma 56 (2004) 265-269
22. Muthu K., Deng J., Romano F., He L.K., Gamelli R., Shankar R., et al. Thermal injury and sepsis modulates β-adrenergic receptors and cAMP responses in monocyte-committed bone marrow cells. J Neuroimmunol 165 (2005) 129-138
23. Maung A.A., Fujimi S., Miller M.L., MacConmara M.P., Mannick J.A., and Lederer J.A. Enhanced TLR-4 reactivity following injury is mediated by increase p38 activation. J Leukoc Biol 78 (2005) 565-573
24. Tissieres P., Dunn-Siergist I., Schappi M., Elson G., Comte R., Nobre V., et al. Soluble MD-2 is an acute phase protein and an opsonin for Gram-negative bacteria. Blood 111 (2008) 2122-2131
25. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nature Immunol 7 (2002) 667-672
26. Hazeki K., Mori Y., and Ui M. Induction of refractoriness of cyclic AMP responses to prostaglandin E1 and epinephrine by prior exposure of guinea pig macrophages to lipopolysaccharide. Arch Biochem Biophys 246 (1986) 772-782
27. Kondomerkos D.J., Kalamidas S.A., and Kotoulas O.B. Effects of cyclic AMP-elevating hormones and autocoids on LPS-activated rat peritoneal, bronchoalveolar and hepatic (Kupffer) macrophages. Cell Biochem Funct 24 (2006) 245-256
28. Ignatowski T.A., Gallant S., and Spengler R.N. Temporal regulation by adrenergic receptor stimulation of macrophage (M phi)-derived tumor necrosis factor (TNF) production post-LPS challenge. J Neuroimmunol 65 (1996) 107-117
29. Harrison T., Samuel B.U., Akompong T., Hamm H., Mohandas N., Lomasney J.W., et al. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science 301 (2003) 1734-1736
30. Pullar C.E., Rizzo A., and Isseroff R.R. Beta-adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. J Biol Chem 28 (2006) 21225-21235
31. Paterson H., Murphy T., Purcell E., Shelley O., Kriynovich S., Lien E., Mannick J., et al. Injury primes the innate immune system for enhanced toll-like receptor reactivity. J Immunol 171 (2003) 1473-1483